Patent 9340618 was granted and assigned to CSL on May, 2016 by the United States Patent and Trademark Office.
The present disclosure provides proteins comprising antigen binding sites of antibodies that bind to interleukin-11 (IL-11) receptor alpha (IL-11Rα) and uses thereof, e.g., in therapy.